Literature DB >> 26966000

CGCG clinical practice guidelines for the management of adult diffuse gliomas.

Tao Jiang1, Ying Mao2, Wenbin Ma3, Qing Mao4, Yongping You5, Xuejun Yang6, Chuanlu Jiang7, Chunsheng Kang8, Xuejun Li9, Ling Chen10, Xiaoguang Qiu11, Weimin Wang12, Wenbin Li13, Yu Yao14, Shaowu Li15, Shouwei Li16, Anhua Wu17, Ke Sai18, Hongmin Bai12, Guilin Li15, Baoshi Chen19, Kun Yao20, Xinting Wei21, Xianzhi Liu21, Zhiwen Zhang22, Yiwu Dai23, Shengqing Lv24, Liang Wang25, Zhixiong Lin16, Jun Dong26, Guozheng Xu27, Xiaodong Ma10, Jinquan Cai7, Wei Zhang19, Hongjun Wang7, Lingchao Chen14, Chuanbao Zhang15, Pei Yang15, Wei Yan28, Zhixiong Liu9, Huimin Hu15, Jing Chen15, Yuqing Liu15, Yuan Yang29, Zheng Wang15, Zhiliang Wang19, Yongzhi Wang19, Gan You19, Lei Han8, Zhaoshi Bao19, Yanwei Liu15, Yinyan Wang19, Xing Fan19, Shuai Liu30, Xing Liu19, Yu Wang30, Qixue Wang8.   

Abstract

The Chinese Glioma Cooperative Group (CGCG) Guideline Panel for adult diffuse gliomas provided recommendations for diagnostic and therapeutic procedures. The Panel covered all fields of expertise in neuro-oncology, i.e. neurosurgeons, neurologists, neuropathologists, neuroradiologists, radiation and medical oncologists and clinical trial experts. The task made clearer and more transparent choices about outcomes considered most relevant through searching the references considered most relevant and evaluating their value. The scientific evidence of papers collected from the literature was evaluated and graded based on the Oxford Centre for Evidence-based Medicine Levels of Evidence and recommendations were given accordingly. The recommendations will provide a framework and assurance for the strategy of diagnostic and therapeutic measures to reduce complications from unnecessary treatment and cost. The guideline should serve as an application for all professionals involved in the management of patients with adult diffuse glioma and also as a source of knowledge for insurance companies and other institutions involved in the cost regulation of cancer care in China.
Copyright © 2016 The Authors. Published by Elsevier Ireland Ltd.. All rights reserved.

Entities:  

Keywords:  CGCG; Glioma; Guideline; Management

Mesh:

Year:  2016        PMID: 26966000     DOI: 10.1016/j.canlet.2016.01.024

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  198 in total

Review 1.  Vaccination in the immunotherapy of glioblastoma.

Authors:  Ziren Kong; Yu Wang; Wenbin Ma
Journal:  Hum Vaccin Immunother       Date:  2017-12-11       Impact factor: 3.452

2.  Treatment strategy and IDH status improve nomogram validity in newly diagnosed GBM patients.

Authors:  Wen Cheng; Chuanbao Zhang; Xiufang Ren; Zheng Wang; Xing Liu; Sheng Han; Anhua Wu
Journal:  Neuro Oncol       Date:  2017-05-01       Impact factor: 12.300

3.  Combinations of four or more CpGs methylation present equivalent predictive value for MGMT expression and temozolomide therapeutic prognosis in gliomas.

Authors:  Rui-Chao Chai; Ke-Nan Zhang; Yu-Qing Liu; Fan Wu; Zheng Zhao; Kuan-Yu Wang; Tao Jiang; Yong-Zhi Wang
Journal:  CNS Neurosci Ther       Date:  2018-08-16       Impact factor: 5.243

4.  Changing paradigms for targeted therapies against diffuse infiltrative gliomas: tackling a moving target.

Authors:  Candice D Carpenter; Iyad Alnahhas; Javier Gonzalez; Pierre Giglio; Vinay K Puduvalli
Journal:  Expert Rev Neurother       Date:  2019-05-27       Impact factor: 4.618

5.  Molecular and clinical characterization of TIM-3 in glioma through 1,024 samples.

Authors:  Guanzhang Li; Zheng Wang; Chuanbao Zhang; Xing Liu; Jinquan Cai; Zhiliang Wang; Huimin Hu; Fan Wu; Zhaoshi Bao; Yanwei Liu; Liang Zhao; Tingyu Liang; Fan Yang; Ruoyu Huang; Wei Zhang; Tao Jiang
Journal:  Oncoimmunology       Date:  2017-07-28       Impact factor: 8.110

Review 6.  Reactive Astrocytes in Glioblastoma Multiforme.

Authors:  Xiudong Guan; Md Nabiul Hasan; Shelly Maniar; Wang Jia; Dandan Sun
Journal:  Mol Neurobiol       Date:  2018-01-23       Impact factor: 5.590

7.  Knockdown of NUPR1 inhibits the proliferation of glioblastoma cells via ERK1/2, p38 MAPK and caspase-3.

Authors:  Jun Li; Siyang Ren; Yongjian Liu; Zhigang Lian; Bin Dong; Yiqun Yao; Yinghui Xu
Journal:  J Neurooncol       Date:  2016-12-20       Impact factor: 4.130

8.  A novel gene signature based on five glioblastoma stem-like cell relevant genes predicts the survival of primary glioblastoma.

Authors:  Ruichao Chai; Kenan Zhang; Kuanyu Wang; Guanzhang Li; Ruoyu Huang; Zheng Zhao; Yanwei Liu; Jing Chen
Journal:  J Cancer Res Clin Oncol       Date:  2018-01-03       Impact factor: 4.553

9.  Novel roles of VAT1 expression in the immunosuppressive action of diffuse gliomas.

Authors:  Pei Yang; Kuanyu Wang; Chuanbao Zhang; Zhiliang Wang; Qi Liu; Jiangfei Wang; Tao Jiang; Xia Shan
Journal:  Cancer Immunol Immunother       Date:  2021-02-12       Impact factor: 6.968

10.  Immune heterogeneity and clinicopathologic characterization of IGFBP2 in 2447 glioma samples.

Authors:  Jinquan Cai; Qun Chen; Yuqiong Cui; Jiawei Dong; Meng Chen; Pengfei Wu; Chuanlu Jiang
Journal:  Oncoimmunology       Date:  2018-02-13       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.